CTBP1 and hypertensive disorder: Another relevant potential underlying pathway in hypertension, metabolic syndrome, dyslipidaemia, and abdominal obesity, is the dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis leading to catecholamine activation of β-adrenergic receptors (β-ARs) [43].